Lifeng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lifeng Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Chen Li
Department of Human Genetics, and Women’s Hospital, Zhejiang University School of Medicine, 310058 Hangzhou, Zhejiang, China
1 shared publication - Chunyan Wang
The Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China
1 shared publication - Cuicui Lin
The Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China
1 shared publication - Huimei Zheng
Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, the Women's Hospital, Zhejiang University School of Medicine, China
1 shared publication - I. V. Kurlovich
Республиканский научно-практический центр «Мать и дитя
1 shared publication - Jawad Safdar
Department of Oral and Maxillofacial Surgery, Dow Dental College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Pregnancy
- Vol. 2026 (1)
Ultrasound‐Indicated Versus Physical Examination‐Indicated Cerclage in Twin Pregnancies Between 24 and 27 + 6 Weeks: An Exploratory Observational Analysis of Pregnancy and Neonatal Outcomes
Background: Recent advancements in assisted reproductive technology and delayed parenthood have led to a surge in twin pregnancies, with a high incidence of preterm birth (PTB) due to cervical insufficiency. Current guidelines recommend cervical cerclage for twin pregnancies before 24 weeks; however, data on cerclage efficacy beyond 24 weeks is scarce. Objective: This exploratory, hypothesis‐generating study is aimed at examining the associations of cervical cerclage on pregnancy duration and neonatal outcomes in twin pregnancies with a short cervix between 24 and 27 + 6 weeks. Methods: This retrospective cohort study, conducted between July 1991 and July 2023 at Women′s Hospital, Zhejiang University School of Medicine, involved twin pregnancies with a short cervix (≤ 25 mm) during the gestational period ranging from 24 weeks to 27 + 6 weeks. Skilled obstetricians performed cervical cerclage. Data on maternal and neonatal outcomes were collected and analyzed using statistical tests, with statistical significance set at p < 0.05. Results: A total of 73 twin pregnancies were analyzed. Participants were categorized into ultrasound‐indicated cerclage group ( n = 22), physical examination‐indicated cerclage group ( n = 33), and control group ( n = 18). The ultrasound‐indicated cerclage group showed significantly longer presentation‐to‐birth intervals (60.77 ± 21.64 days, p = 0.007) and higher birth weights (larger twin: 2273.33 ± 566.09 g, p = 0.026; smaller twin: 2086.90 ± 526.58 g, p = 0.029) compared with the control group. No significant differences were found in gestational age at delivery, Apgar scores, cesarean delivery rates, maternal morbidity, and neonatal morbidity among both groups. Conclusions: Ultrasound‐indicated cerclage in twin pregnancies at 24–27 + 6 weeks was observed to prolong presentation‐to‐birth interval and increase birth weight, whereas physical examination‐indicated cerclage showed no statistically significant association with the measured outcomes. A randomized controlled clinical trial is needed to validate these findings.
- 1 January 2026
- Published by Wiley in Journal of Pregnancy
- Vol. 2026 (1)
Open AccessUltrasound‐Indicated Versus Physical Examination‐Indicated Cerclage in Twin Pregnancies Between 24 and 27 + 6 Weeks: An Exploratory Observational Analysis of Pregnancy and Neonatal Outcomes
Background: Recent advancements in assisted reproductive technology and delayed parenthood have led to a surge in twin pregnancies, with a high incidence of preterm birth (PTB) due to cervical insufficiency. Current guidelines recommend cervical cerclage for twin pregnancies before 24 weeks; however, data on cerclage efficacy beyond 24 weeks is scarce. Objective: This exploratory, hypothesis‐generating study is aimed at examining the associations of cervical cerclage on pregnancy duration and neonatal outcomes in twin pregnancies with a short cervix between 24 and 27 + 6 weeks. Methods: This retrospective cohort study, conducted between July 1991 and July 2023 at Women′s Hospital, Zhejiang University School of Medicine, involved twin pregnancies with a short cervix (≤ 25 mm) during the gestational period ranging from 24 weeks to 27 + 6 weeks. Skilled obstetricians performed cervical cerclage. Data on maternal and neonatal outcomes were collected and analyzed using statistical tests, with statistical significance set at p < 0.05. Results: A total of 73 twin pregnancies were analyzed. Participants were categorized into ultrasound‐indicated cerclage group ( n = 22), physical examination‐indicated cerclage group ( n = 33), and control group ( n = 18). The ultrasound‐indicated cerclage group showed significantly longer presentation‐to‐birth intervals (60.77 ± 21.64 days, p = 0.007) and higher birth weights (larger twin: 2273.33 ± 566.09 g, p = 0.026; smaller twin: 2086.90 ± 526.58 g, p = 0.029) compared with the control group. No significant differences were found in gestational age at delivery, Apgar scores, cesarean delivery rates, maternal morbidity, and neonatal morbidity among both groups. Conclusions: Ultrasound‐indicated cerclage in twin pregnancies at 24–27 + 6 weeks was observed to prolong presentation‐to‐birth interval and increase birth weight, whereas physical examination‐indicated cerclage showed no statistically significant association with the measured outcomes. A randomized controlled clinical trial is needed to validate these findings.
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models
Endometriosis is an estrogen‐dependent chronic inflammatory disease that affects approximately 10% of women of reproductive age and up to 50% of women with infertility. The heterogeneity of the disease makes accurate diagnosis and treatment a clinical challenge. In this study, we generated two models of endometriosis: the first in rats and the second using human ectopic endometrial stromal cells (HEcESCs) derived from the lesion tissues of endometriosis patients. We then applied resveratrol to assess its therapeutic potential. Resveratrol intervention had significant efficacy to attenuate lesion size and to rectify aberrant lipid profiles of model rats. Lipidomic analysis revealed significant lipidomic alterations, including notable increases of sphingolipids and decreases of both glycerolipids and most phospholipids. Upon resveratrol application, both proliferation capacity and invasiveness parameters decreased, and the early apoptosis proportion increased for HEcESCs. The activation of PPARα was also noted as a factor potentially contributing to recovery from endometriosis in both models. Our study provides valuable insight into the mechanisms of resveratrol in endometriosis and therefore strengthens the potential for optimizing resveratrol treatment for this disease.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessLipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models
Endometriosis is an estrogen‐dependent chronic inflammatory disease that affects approximately 10% of women of reproductive age and up to 50% of women with infertility. The heterogeneity of the disease makes accurate diagnosis and treatment a clinical challenge. In this study, we generated two models of endometriosis: the first in rats and the second using human ectopic endometrial stromal cells (HEcESCs) derived from the lesion tissues of endometriosis patients. We then applied resveratrol to assess its therapeutic potential. Resveratrol intervention had significant efficacy to attenuate lesion size and to rectify aberrant lipid profiles of model rats. Lipidomic analysis revealed significant lipidomic alterations, including notable increases of sphingolipids and decreases of both glycerolipids and most phospholipids. Upon resveratrol application, both proliferation capacity and invasiveness parameters decreased, and the early apoptosis proportion increased for HEcESCs. The activation of PPARα was also noted as a factor potentially contributing to recovery from endometriosis in both models. Our study provides valuable insight into the mechanisms of resveratrol in endometriosis and therefore strengthens the potential for optimizing resveratrol treatment for this disease.